Healthcare provider profile · identity verified

Tushar G Patel, MD

Internal Medicine · CHANTILLY, VA · NPI 1174636716

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	629	193
Amlodipine Besylate	Amlodipine Besylate	317	92
Levothyroxine Sodium	Levothyroxine Sodium	239	70
Metformin Hcl Er	Metformin Hcl	233	69
Losartan Potassium	Losartan Potassium	208	61
Pantoprazole Sodium	Pantoprazole Sodium	191	63
Rosuvastatin Calcium	Rosuvastatin Calcium	186	60
Gabapentin	Gabapentin	182	47
Lisinopril	Lisinopril	175	45
Tamsulosin Hcl	Tamsulosin Hcl	143	43
Metformin Hcl	Metformin Hcl	138	43
Metoprolol Succinate	Metoprolol Succinate	138	43
Simvastatin	Simvastatin	127	37
Atenolol	Atenolol	91	25
Glimepiride	Glimepiride	87	26
Allopurinol	Allopurinol	82	24
Finasteride	Finasteride	78	19
Telmisartan	Telmisartan	75	25
Furosemide	Furosemide	70	33
Carvedilol	Carvedilol	68	21
Pravastatin Sodium	Pravastatin Sodium	68	18
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	60	17
Hydrochlorothiazide	Hydrochlorothiazide	56	17
Omeprazole	Omeprazole	56	19
Zolpidem Tartrate	Zolpidem Tartrate	56	11
Albuterol Sulfate Hfa	Albuterol Sulfate	53	25
Spironolactone	Spironolactone	52	15
Escitalopram Oxalate	Escitalopram Oxalate	50	16
Sertraline Hcl	Sertraline Hcl	50	15
Tramadol Hcl	Tramadol Hcl	50	suppressed
Trazodone Hcl	Trazodone Hcl	50	15
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	48	13
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	46	14
Duloxetine Hcl	Duloxetine Hcl	44	suppressed
Famotidine	Famotidine	44	16
Synthroid	Levothyroxine Sodium	44	11
Eliquis	Apixaban	43	17
Diclofenac Sodium	Diclofenac Sodium	40	25
Clopidogrel	Clopidogrel Bisulfate	39	14
Glipizide Er	Glipizide	38	12
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	38	15
Montelukast Sodium	Montelukast Sodium	38	11
Olmesartan Medoxomil	Olmesartan Medoxomil	38	11
Ozempic	Semaglutide	36	suppressed
Potassium Chloride	Potassium Chloride	36	11
Prednisone	Prednisone	35	21
Clonazepam	Clonazepam	34	suppressed
Telmisartan-Hydrochlorothiazid	Telmisartan/Hydrochlorothiazid	34	suppressed
Jardiance	Empagliflozin	33	14
Azithromycin	Azithromycin	32	30
Nystatin-Triamcinolone	Nystatin/Triamcinolone Acet	32	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	32	21
Ezetimibe	Ezetimibe	30	suppressed
Fluticasone Propionate	Fluticasone Propionate	30	suppressed
Celecoxib	Celecoxib	29	suppressed
Lorazepam	Lorazepam	29	suppressed
Mirtazapine	Mirtazapine	29	11
Bupropion Xl	Bupropion Hcl	26	suppressed
Nifedipine Er	Nifedipine	26	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	26	17
Donepezil Hcl	Donepezil Hcl	25	suppressed
Farxiga	Dapagliflozin Propanediol	25	suppressed
Levocetirizine Dihydrochloride	Levocetirizine Dihydrochloride	25	suppressed
Tradjenta	Linagliptin	25	suppressed
Cefuroxime	Cefuroxime Axetil	24	20
Januvia	Sitagliptin Phosphate	24	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	24	suppressed
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	22	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	21	suppressed
Xarelto	Rivaroxaban	21	suppressed
Clotrimazole-Betamethasone	Clotrimazole/Betamethasone Dip	20	suppressed
Meloxicam	Meloxicam	20	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	20	suppressed
Clonidine Hcl	Clonidine Hcl	19	suppressed
Hydralazine Hcl	Hydralazine Hcl	19	suppressed
Irbesartan	Irbesartan	19	suppressed
Janumet	Sitagliptin Phos/Metformin Hcl	19	suppressed
Metoprolol Tartrate	Metoprolol Tartrate	19	suppressed
Pregabalin	Pregabalin	19	suppressed
Ropinirole Hcl	Ropinirole Hcl	19	suppressed
Alprazolam	Alprazolam	18	suppressed
Cefdinir	Cefdinir	18	17
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	18	13
Liothyronine Sodium	Liothyronine Sodium	18	suppressed
Myrbetriq	Mirabegron	18	suppressed
Glipizide	Glipizide	17	suppressed
Diazepam	Diazepam	16	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	16	suppressed
Ibuprofen	Ibuprofen	16	suppressed
Ondansetron Odt	Ondansetron	16	suppressed
Ramipril	Ramipril	16	suppressed
Alfuzosin Hcl Er	Alfuzosin Hcl	15	suppressed
Citalopram Hbr	Citalopram Hydrobromide	15	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	15	suppressed
Fluconazole	Fluconazole	15	suppressed
Metronidazole	Metronidazole	15	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	15	suppressed
Vitamin D2	Ergocalciferol (Vitamin D2)	15	suppressed
Amoxicillin	Amoxicillin	14	suppressed
Nebivolol Hcl	Nebivolol Hcl	14	suppressed
Propranolol Hcl	Propranolol Hcl	14	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	13	13
Benazepril Hcl	Benazepril Hcl	13	suppressed
Ketoconazole	Ketoconazole	13	suppressed
Latanoprost	Latanoprost	13	suppressed
Paxlovid	Nirmatrelvir/Ritonavir	13	13
Bisoprolol Fumarate	Bisoprolol Fumarate	12	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	12	suppressed
Colesevelam Hcl	Colesevelam Hcl	12	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	12	suppressed
Warfarin Sodium	Warfarin Sodium	12	suppressed
Acyclovir	Acyclovir	11	suppressed
Amiodarone Hcl	Amiodarone Hcl	11	suppressed
Dutasteride	Dutasteride	11	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	11	suppressed
Fluticasone-Salmeterol Hfa	Fluticasone Propion/Salmeterol	11	suppressed
Mupirocin	Mupirocin	11	suppressed
Solifenacin Succinate	Solifenacin Succinate	11	suppressed
Tolterodine Tartrate Er	Tolterodine Tartrate	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error